Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent

PURPOSE: The aim of this study was to examine the rate and timing of hemoglobin decline from <10 g/dL to <9 g/dL in cancer patients receiving chemotherapy. METHODS: Pooled data from the placebo arms of six randomized, controlled trials (RCTs) of darbepoetin alfa and data from an aggregated US...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirker, Robert, Pirolli, Melissa, Quigley, Jane, Hulnick, Scott, Legg, Jason, Collins, Helen, Vansteenkiste, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584249/
https://www.ncbi.nlm.nih.gov/pubmed/23096072
http://dx.doi.org/10.1007/s00520-012-1617-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584249/
https://www.ncbi.nlm.nih.gov/pubmed/23096072
http://dx.doi.org/10.1007/s00520-012-1617-2

Ejemplares similares